Secondary screening for early pancreatic cancer

The best chance of long term cure from pancreatic cancer is through early diagnosis. However there is no single test which can detect every emerging cancer. Screening for pancreatic cancer is particularly challenging and there is currently no proven programme for the surveillance of individuals estimated to be an increased risk of developing this cancer.

 

EUROPAC has developed a secondary screening study for individuals at a high risk of pancreatic cancer. Our protocol combines imaging and blood testing with the option of molecular analysis of pancreatic juice and the aim is to combine these various tests to improve the overall accuracy of the screen.

 

Access to EUROPAC's secondary screening study is via registration with the EUROPAC registry, allowing a full risk assessment. Although every family is considered on an individual basis, screening usually takes place from the age of 40. More information about entry criteria and the tests involved can be found in the HP screening and FPC screening sections of this website.

 

The secondary screening study is a separate study to the registry and no one registered with EUROPAC is obliged to undergo surveillance. Not taking part in the screening study will in no way affect participation with the registry.

 

All screening methods have advantages and disadvantages, including associated risks. These are fully discussed prior to entry onto the study.